Angiogenesis inhibitors for colorectal cancer: A review of the clinical data

Torben Frøstrup Hansen*, Camilla Qvortrup, Per Pfeiffer

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

7 Downloads (Pure)


Since the late 1990s, therapy for metastatic colorectal cancer (mCRC) has changed con-siderably, and the combination of doublet or triplet chemotherapy and a targeted agent are now routinely used. The targeting of angiogenesis, the development of new blood vessels, represents a key element in the overall treatment strategy. Since the approval in 2004 of the first anti-angiogenetic drug, multiple agents have been approved and others are currently under investigation. We present an overview of the recent literature on approved systemic treatment of mCRC, with a focus on anti-angiogenic drugs, and current treatment approaches, and elaborate on the future role of angio-genesis in colorectal cancer as seen from a clinical perspective. The treatment of mCRC, in general, has changed from “one strategy fits all” to a more personalized approach. This is, however, not entirely the case for anti-angiogenetic treatments, partly due to a lack of validated biomarkers. The anti-angiogenetic standard treatment at the present primarily includes monoclonal antibodies. The therapeutic field of angiogenesis, however, has received increased interest after the introduction of newer combinations. These approaches will likely change the current treatment strategy, once again, to the overall benefit of patients.

Original languageEnglish
Article number1031
Issue number5
Number of pages19
Publication statusPublished - 1. Mar 2021


  • Angiogenesis
  • Colorectal cancer
  • Monoclonal antibodies
  • Small molecule tyrosine kinase inhibitors


Dive into the research topics of 'Angiogenesis inhibitors for colorectal cancer: A review of the clinical data'. Together they form a unique fingerprint.

Cite this